Open Payments

KFH - ANTIOCH

Type
Teaching hospital
Where
ANTIOCH, CA
Medicare CCN
050760
Received
$6,769,730 in 440 records, 2019 ($1,326 general, $6,768,403 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2019General payment6$1,326
2019Research payment434$6,768,403

By company

CompanyRecordsAmountYears
PFIZER INC.430$6,750,9452019
MEDIVATION LLC.5$17,5312019
Cochlear Americas4$1,1752019
Zimmer Biomet Holdings, Inc.1$782019

By nature of payment

NatureRecordsAmount
Research payment434$6,768,403
Grant4$1,175
Gift1$78
Travel and Lodging1$72

Records

DateCompanyAmountNatureFormProductStudyYear
2019-12-31Zimmer Biomet Holdings, Inc.$78GiftIn-kind items and servicesZimmer Biomet Instruments and Implants Device, General2019
2019-12-23PFIZER INC.$314,744Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESCRCPREDICTORS OF PNEUMOCOCCAL VACCINATION PNEUMOCOCCAL VACCINE EFFECTIVENESS AND TRENDS IN PNEUMONIA2019
2019-12-20PFIZER INC.$2,045Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC2019
2019-12-19PFIZER INC.$6,278Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512019
2019-12-18PFIZER INC.$30,600Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-18PFIZER INC.$20,400Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-18PFIZER INC.$17,340Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-18PFIZER INC.$5,940Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-18PFIZER INC.$4,149Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-18PFIZER INC.$4,070Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-18PFIZER INC.$4,050Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-18PFIZER INC.$2,860Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-18PFIZER INC.$2,775Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-18PFIZER INC.$1,950Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-18PFIZER INC.$1,593Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-18PFIZER INC.$1,003Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-18PFIZER INC.$885Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-12PFIZER INC.$35,700Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-12PFIZER INC.$7,260Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-12PFIZER INC.$4,950Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-12PFIZER INC.$3,149Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-12PFIZER INC.$2,035Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-12PFIZER INC.$944Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-12PFIZER INC.$837Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-12-12PFIZER INC.$837Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-12-12PFIZER INC.$629Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-12PFIZER INC.$629Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-12PFIZER INC.$629Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-12PFIZER INC.$418Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-12-12PFIZER INC.$418Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-12-11PFIZER INC.$16,830Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-11PFIZER INC.$3,630Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-11PFIZER INC.$2,475Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-11PFIZER INC.$973Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-06PFIZER INC.$9,574Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512019
2019-12-05PFIZER INC.$2,099Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-05PFIZER INC.$629Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-05PFIZER INC.$314Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-05PFIZER INC.$314Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-12-04PFIZER INC.$3,749Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC2019
2019-11-28PFIZER INC.$16,830Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-28PFIZER INC.$4,723Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-28PFIZER INC.$3,520Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-28PFIZER INC.$3,519Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-28PFIZER INC.$2,930Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-11-28PFIZER INC.$2,880Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-28PFIZER INC.$2,661Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-28PFIZER INC.$2,512Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-11-28PFIZER INC.$2,512Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-11-28PFIZER INC.$2,400Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-28PFIZER INC.$1,889Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-28PFIZER INC.$1,574Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-28PFIZER INC.$1,259Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-28PFIZER INC.$1,256Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-11-28PFIZER INC.$737Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-28PFIZER INC.$600Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-28PFIZER INC.$314Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-28PFIZER INC.$300Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-27MEDIVATION LLC.$2,965Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 OPENLABEL RANDOMIZED PARALLEL2ARMMULTICENTER STUDY OF TALAZOPARIBBMN 673 VERSUS PHYSICIANS CHOICE IN GERMLINE 2019
2019-11-27MEDIVATION LLC.$715Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 OPENLABEL RANDOMIZED PARALLEL2ARMMULTICENTER STUDY OF TALAZOPARIBBMN 673 VERSUS PHYSICIANS CHOICE IN GERMLINE 2019
2019-11-23PFIZER INC.$4,471Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512019
2019-11-21PFIZER INC.$2,386Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC2019
2019-11-20PFIZER INC.$17,250Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-20PFIZER INC.$7,632Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-20PFIZER INC.$2,346Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-20PFIZER INC.$2,346Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-20PFIZER INC.$2,204Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-20PFIZER INC.$2,204Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-20PFIZER INC.$1,716Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-20PFIZER INC.$1,259Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-20PFIZER INC.$314Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-18PFIZER INC.$297,107Research paymentCash or cash equivalentZITHROMAX Drug, INFECTIOUS DISEASESTHE ACUTE EFFECTS OF AZITHROMYCIN USE ON CARDIOVASCULAR MORTALITY AS COMPARED WITH AMOXICILLIN2019
2019-11-18PFIZER INC.$37,356Research paymentCash or cash equivalentATOPIC DERMATITIS STANDING COHORT USING A COHORT OF KAISER PERMANENTE NORTHERN CALIFORNIA MEMBERS KPNC2019
2019-11-13PFIZER INC.$16,525Research paymentCash or cash equivalentA RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG2019
2019-11-13PFIZER INC.$11,818Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-13PFIZER INC.$3,291Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-13PFIZER INC.$2,976Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-13PFIZER INC.$2,877Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-13PFIZER INC.$2,574Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-13PFIZER INC.$944Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-13PFIZER INC.$629Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-13PFIZER INC.$629Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-02PFIZER INC.$5,451Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512019
2019-11-01PFIZER INC.$1,363Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC2019
2019-10-30PFIZER INC.$5,559Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-10-30PFIZER INC.$2,830Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-10-30PFIZER INC.$1,992Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-10-30PFIZER INC.$837Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-10-30MEDIVATION LLC.$585Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 OPENLABEL RANDOMIZED PARALLEL2ARMMULTICENTER STUDY OF TALAZOPARIBBMN 673 VERSUS PHYSICIANS CHOICE IN GERMLINE 2019
2019-10-24PFIZER INC.$13,947Research paymentCash or cash equivalentA PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 42019
2019-10-24PFIZER INC.$12,745Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512019
2019-10-24PFIZER INC.$9,262Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ2019
2019-10-24PFIZER INC.$5,834Research paymentCash or cash equivalentA PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 42019
2019-10-24PFIZER INC.$5,557Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ2019
2019-10-24PFIZER INC.$4,816Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ2019
2019-10-24PFIZER INC.$3,300Research paymentCash or cash equivalentA PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 42019
2019-10-23PFIZER INC.$13,300Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-23PFIZER INC.$9,633Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ2019
2019-10-23PFIZER INC.$8,151Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ2019
2019-10-23PFIZER INC.$7,410Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ2019
2019-10-23PFIZER INC.$6,940Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-23PFIZER INC.$4,464Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-23PFIZER INC.$4,439Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-23PFIZER INC.$4,149Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-23PFIZER INC.$3,360Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-23PFIZER INC.$2,661Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-23PFIZER INC.$2,574Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-23PFIZER INC.$700Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-23PFIZER INC.$350Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-22PFIZER INC.$5,000Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC2019
2019-10-22PFIZER INC.$72Travel and LodgingIn-kind items and services2019
2019-10-09PFIZER INC.$10,509Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-09PFIZER INC.$4,594Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-09PFIZER INC.$2,951Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-09PFIZER INC.$2,031Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-09PFIZER INC.$1,488Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-09PFIZER INC.$1,488Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-08PFIZER INC.$7,365Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC2019
2019-10-02PFIZER INC.$10,614Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-02PFIZER INC.$7,953Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-02PFIZER INC.$5,514Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-02PFIZER INC.$2,964Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-02PFIZER INC.$2,420Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-02PFIZER INC.$2,019Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-02PFIZER INC.$1,920Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-02PFIZER INC.$1,716Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-02PFIZER INC.$1,475Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-02PFIZER INC.$400Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-02PFIZER INC.$200Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-10-01PFIZER INC.$7,875Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512019
2019-09-25PFIZER INC.$8,730Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-09-25PFIZER INC.$3,656Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-09-25PFIZER INC.$3,649Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-09-25PFIZER INC.$2,218Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-09-19PFIZER INC.$8,294Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC2019
2019-09-18PFIZER INC.$6,607Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-09-18PFIZER INC.$5,841Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-09-18PFIZER INC.$5,211Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-09-18PFIZER INC.$3,822Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-09-18PFIZER INC.$3,433Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-09-18PFIZER INC.$3,192Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-09-18PFIZER INC.$2,574Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-09-18PFIZER INC.$1,716Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-09-11PFIZER INC.$15,770Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-09-11PFIZER INC.$14,431Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-09-11PFIZER INC.$12,189Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-09-11PFIZER INC.$7,934Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-09-11PFIZER INC.$6,156Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-09-11PFIZER INC.$5,853Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-09-11PFIZER INC.$4,767Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-09-11PFIZER INC.$4,594Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-09-04PFIZER INC.$6,068Research paymentCash or cash equivalentA PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF066512019
2019-08-28PFIZER INC.$22,032Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-28PFIZER INC.$8,188Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-28PFIZER INC.$7,657Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-28PFIZER INC.$6,712Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-28PFIZER INC.$6,298Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ2019
2019-08-28PFIZER INC.$4,594Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-28PFIZER INC.$3,334Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ2019
2019-08-28PFIZER INC.$3,180Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-28PFIZER INC.$2,877Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-28PFIZER INC.$2,223Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ2019
2019-08-28PFIZER INC.$2,118Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-28PFIZER INC.$2,000Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-28PFIZER INC.$1,950Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-28PFIZER INC.$1,500Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-28PFIZER INC.$1,250Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-28PFIZER INC.$1,000Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-28PFIZER INC.$750Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-28PFIZER INC.$750Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-28PFIZER INC.$500Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-27PFIZER INC.$19,091Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC2019
2019-08-21PFIZER INC.$5,223Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-08-21PFIZER INC.$4,712Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-08-21PFIZER INC.$2,218Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-08-21PFIZER INC.$1,431Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-08-16PFIZER INC.$10,466Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC2019
2019-08-14PFIZER INC.$41,051Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-14PFIZER INC.$18,247Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-14PFIZER INC.$16,388Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-14PFIZER INC.$14,634Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-14PFIZER INC.$10,954Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-14PFIZER INC.$10,787Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-14PFIZER INC.$8,768Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-14PFIZER INC.$7,799Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-14PFIZER INC.$2,400Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-14PFIZER INC.$500Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-14PFIZER INC.$250Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-03PFIZER INC.$33,540Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC2019
2019-07-24PFIZER INC.$10,571Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-07-24PFIZER INC.$10,522Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-07-24PFIZER INC.$7,521Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-07-24PFIZER INC.$6,360Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-07-24PFIZER INC.$5,509Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-07-24PFIZER INC.$4,680Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-07-24PFIZER INC.$4,668Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-07-24PFIZER INC.$4,068Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-07-24PFIZER INC.$4,038Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-07-24PFIZER INC.$3,792Research paymentCash or cash equivalentPREVNAR - 13 Biological, VACCINESA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V2019
2019-07-24PFIZER INC.$3,192Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019

The latest 200 records of 440.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Contra Costa CountyAntioch city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Antioch, CA, county Contra Costa County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Antioch, CA
County
Contra Costa County, CA
State
California
Population B01003116,4771,165,01239,287,377
Population, 2020 census P1115,2911,165,92739,538,223
Median age B0100238.440.537.9
Under 18 B0100122.8%22.0%22.0%
65 and over B0100114.3%17.1%15.7%
Households B1100137,381414,41713,548,091
Foreign born B0500224.6%26.6%27.0%
Median household income B19013$97,465$127,229$99,122
Median family income B19113$109,115$148,679$113,346
Per capita income B19301$41,008$62,927$49,513
Poverty rate B1700111.4%8.4%12.0%
Unemployment rate B230257.4%6.5%6.6%
Civilian labor force B2302560,709608,62020,068,466
Mean commute (minutes) B0801342.035.328.7
Bachelor's degree or higher B1500323.9%45.2%37.1%
Housing units B2500138,629429,26014,644,735
Owner-occupied B2500363.6%68.0%55.9%
Renters B2500336.4%32.0%44.1%
Median home value B25077$629,700$866,800$734,700
Median gross rent B25064$2,278$2,375$2,036
White, not Hispanic B0300223.4%38.1%33.8%
Black B0300218.2%7.9%5.2%
Hispanic or Latino B0300235.6%27.6%40.2%
Asian B0300213.9%18.6%15.3%
American Indian and Alaska Native B030020.5%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Antioch, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.